NCT06464614 2024-06-18
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT03787251 2022-04-19
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Withdrawn
NCT05049681 2021-09-20
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The First Affiliated Hospital of Zhengzhou University
Phase 3 Unknown
NCT03274011 2021-01-26
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Completed
NCT03671265 2019-01-09
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT03285906 2017-09-18
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT02544737 2016-08-26
Apatinib for Metastatic Esophageal Cancer.
Hangzhou Cancer Hospital
Phase 2 Unknown
NCT02683655 2016-02-17
Study of Apatinib in Metastatic Esophageal Cancer
Huai'an First People's Hospital
Phase 2 Unknown